| References |
1. Shepard AR, Conrow RE, Pang IH, Jacobson N, Rezwan M, Rutschmann K, Auerbach D, Sriramaratnam R, Cornish VW. Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen. ACS Chem Biol. 2013 Mar 15;8(3):549-58. doi: 10.1021/cb300296m. 2. Stalmans I, Callanan DG, Dirks MS, Moster MR, Robin AL, Van Calster J, Scheib SA, Dickerson JE Jr, Landry TA, Bergamini MV. Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial. J Ocul Pharmacol Ther. 2012 Dec;28(6):559-6doi: 10.1089/jop.2012.006Epub 2012 Aug PubMed PMID: 22860637; PubMed Central PMCID: PMC3505827. 3. Missel P, Chastain J, Mitra A, Kompella U, Kansara V, Duvvuri S, Amrite A, Cheruvu N. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther. 2010 Apr;26(2):137-46. doi: 10.1089/jop.2009.013PubMed PMID: 20415622; PubMed Central PMCID: PMC3158576. 4. Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castaño ME. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2860-doi: 10.1167/iovs.09-4500. Epub 2010 Jan 27. PubMed PMID: 20107171; PubMed Central PMCID: PMC2891454. |
